文献速递甲状腺与浅表介入US

BRAF V600E突变与甲状腺乳头状癌微波消融结局关系的临床研究:倾向性评分匹配队列研究

Clinic Study on the Relationship Between BRAF V600E Mutation and Outcomes of Microwave Ablation in Papillary Thyroid Carcinoma: A Propensity Score-matched Cohort Study.
PubMed 文献 · Acad Radiol · 2025-11-12

回顾性纳入2016年3月至2024年5月接受超声引导下微波消融的683例T1N0M0甲状腺乳头状癌患者,其中BRAF阳性515例(75.4%)、阴性168例(24.6%)。倾向性评分匹配(2:1)后纳入BRAF阳性336例与阴性168例,平均随访26个月,两组疾病进展率分别为1.49%(5/336)与1.19%(2/168),无进展生存期无显著差异(log-rank p=0.78;HR 0.795;95%CI 0.154-4.101)。结论认为无论BRAF V600E突变状态如何,微波消融在T1N0M0甲状腺乳头状癌中均获得有效局部控制且并发症率低。

要点

  • T1N0M0甲状腺乳头状癌微波消融后,BRAF阳性与阴性组无进展生存期无显著差异(log-rank p=0.78)。
  • 匹配后平均随访26个月,BRAF阳性组疾病进展1.49%(5/336),阴性组1.19%(2/168)。
  • 两组消融区完全消失的中位时间均为13个月,主要并发症为暂时性声音嘶哑且发生率低。

核心结论

  • 在T1N0M0甲状腺乳头状癌中,无论BRAF V600E突变状态如何,微波消融均获得有效局部控制且并发症率低。

研究设计与样本

  • 回顾性队列研究,纳入2016年3月至2024年5月接受超声引导下微波消融、经细胞学或组织学确诊的T1N0M0甲状腺乳头状癌患者683例(BRAF阳性515例、阴性168例),采用倾向性评分匹配(2:1)后纳入BRAF阳性336例与阴性168例。

关键影像表现/征象

  • 两组消融区完全消失的中位时间均为13个月(log-rank p=0.51)。
  • 主要并发症为暂时性声音嘶哑,并发症率低且组间可比(4.76% vs 4.17%,p=0.825),无手术相关死亡。

诊断标准与关键数值

  • 匹配后BRAF阳性组疾病进展1.49%(5/336,4个新发肿瘤和1个淋巴结转移),BRAF阴性组1.19%(2/168,1个新发肿瘤和1个淋巴结转移),总体发生率低(1.49% vs 1.19%,p>0.999)。
  • 两组无进展生存期无显著差异(log-rank p=0.78;HR 0.795;95%CI 0.154-4.101)。
  • 1年、3年和5年无进展生存率组间可比(5年:97.8% vs 95.7%;所有p>0.999)。

临床应用与阅片要点

  • 对于T1N0M0甲状腺乳头状癌,微波消融后BRAF V600E突变状态似乎不影响疾病进展和无进展生存期。
  • 随访中需关注消融区体积缩小比率变化及新发肿瘤或淋巴结转移,但原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Microwave ablation (MWA) has emerged as a minimally invasive alternative to surgery for selected cases of papillary thyroid carcinoma (PTC). Although the BRAF V600E mutation is a well-established predictor of aggressive clinicopathologic features in surgical cohorts, its influence on ablation outcomes remains unclear.

METHODS: We retrospectively reviewed 683 patients with cytologically or histologically confirmed T1N0M0 PTC who underwent ultrasound-guided MWA between March 2016 and May 2024. Among them, 515 (75.4%) were BRAF-positive and 168 (24.6%) were BRAF-negative. Propensity score matching (PSM) was applied to balance demographic, clinical, and tumor characteristics. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were procedure-related complications and longitudinal changes in the volume reduction ratio (VRR).

RESULTS: After PSM (2:1), 336 BRAF-positive and 168 BRAF-negative patients were included. During a mean follow-up of 26 months, disease progression occurred in 1.49% (5/336) of BRAF-positive patients (4 new tumors and 1 nodal metastasis) and 1.19% (2/168) of BRAF-negative patients (1 new tumor and 1 nodal metastasis). The overall incidence of disease progression was low (1.49% vs. 1.19%; p > 0.999), with no significant difference in PFS between groups (log-rank p = 0.78; HR, 0.795; 95% CI, 0.154-4.101). The 1-, 3-, and 5-year PFS rates were comparable (5-year: 97.8% vs. 95.7%; all p > 0.999). The median time to complete ablation zone disappearance was 13 months in both groups (log-rank p = 0.51). The main complication was transient hoarseness; complication rates were low and comparable (4.76% vs. 4.17%, p = 0.825), and no procedure-related mortality occurred.

CONCLUSIONS: MWA achieved effective local control with low complication rates in T1N0M0 PTC regardless of BRAF V600E mutation status.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Li S, Wei Y, Zhao ZL, et al. Clinic Study on the Relationship Between BRAF V600E Mutation and Outcomes of Microwave Ablation in Papillary Thyroid Carcinoma: A Propensity Score-matched Cohort Study. Acad Radiol. 2025. PMID: 41233269. doi:10.1016/j.acra.2025.10.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。